Thawing System: innovative advancement in biopharmaceutical sector

2018-05-14 11:13:07

Market Overview
According to a new report published by Reports Monitor titled, “Thawing System Market by Component, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the Thawing System market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. 


Thawing is phenomenon that refers to defrosting in which frozen product is taken from a frozen state to a temperature where there is no presence of residual ice.  Thawing is regularly considered as just the inversion of the freezing process. At the time of product requirement, defrosting is performed in temperature controlled space to guarantee the item is restored. Thawing system innovation has positively influenced research and development programmes as it minimizes the amount of sample required to study. 


More Insightful Information | Request a Sample Copy @ http://bit.ly/2GbL62M


Factors influencing the market Scenario
Drug manufacturing process in biopharmaceutical companies highly demand for thawing system in order to transport and store pharmaceutical products. Furthermore, Expanding accentuation on biorepositories to extend their capacity limits and innovative headway in sample thawing framework additionally drives the development of the market. Moreover, developing use of thawed cells in the examination and treatment of tumor and diabetes and in addition surging need of cryopreserved blood products for various purpose fuels the growth of the thawing system market. However, high cost of the mechanization and less optimality for large batch of sample may oblige the market development. Developing economies and rising spotlight on R&D of cell treatments offer better chances to penetrate the market. Issues identified with biospecimen test acquirement remains as greatest test to the market.


The global thawing system market is segmented on the basis of type, sample type, end-user and region. On the basis of type the market is split into manual devices and automated devices. Considering sample type the market is classified as blood, embryos, ovum, semen and other samples.  In terms of end- user the market is bifurcated into blood bank & transfusion centers, cord blood & stem cell banks, hospitals & diagnostic laboratories, research & academic institutes, biotechnology & pharmaceutical industries and tissue banks.


Major segments of the market
Rising prevalence of blood diseases and increasing requirement for various types of blood products is majorly responsible for driving the blood sample segment. By end-user segment the blood bank and transfusion center is led predominantly owing to heavy burden of chronic disorders demanding for blood transfusion and growing number of blood banks. While cheap cost and broader presence of manual devices across the globe certainly affects manual device segment. 


Competitive Landscape
The key players operating in the market are Helmer Scientific, BioCision, GE Healthcare, Thermo Fisher Scientific, Boekel Scientific, Cardinal Health Inc., Barkey  GmbH & Co. KG,, Sartorius, Sarstedt and CytoTherm Lp. 
For instance, Cook Regentec, developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient, and Asymptote Ltd. on 29th November 2016 announced the launch of the CellSeal® Automated Thawing System. This new system is part of collaboration between the two companies. It offers users with through control in the thawing of cryogenically frozen cells, which is a crucial step in the delivery of cell and gene therapies. 


About Garner Insights:

We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.


Contact Us:

Kevin Thomas

Direct:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected] 

Related Press Releases